Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL

Journal of Bone and Mineral Research

Volumn 29, Issue 6, 2014, Pages 1431-1445

  Ohba, Tetsuro ^a   Cole, Heather A ^a   Cates, Justin M M ^a   Slosky, David A ^a   Haro, Hirotaka ^b   Ando, Takashi ^b   Schwartz, Herbert S ^a   Schoenecker, Jonathan G ^a,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BISPHOSPHONATES; MCP 1; OSTEOCLAST; OSTEOSARCOMA; RANKL OPG

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; OSTEOPROTEGERIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; ATTENUATION; BONE DESTRUCTION; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; MONOCYTE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PROTEIN EXPRESSION; ANIMAL; BLOOD; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL PROLIFERATION; COMPLICATION; DRUG EFFECTS; DRUG THERAPY; ETIOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CCL2; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MICE; MONOCYTES; NEOPLASM INVASIVENESS; OSTEOCLASTS; OSTEOGENESIS; OSTEOLYSIS; OSTEOPROTEGERIN; OSTEOSARCOMA; RANK LIGAND;

EID: 84896948913     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2182     Document Type: Article

References (50)

1. Wunder JS, Nielsen TO, Maki RG, O'Sullivan B, Alman BA., Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol. 2007; 8 (6): 513-24.
2. Lipton A, Goessl C., Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone. 2011; 48 (1): 96-9.
3. Uppal R, Medarova Z, Farrar CT, Dai G, Moore A, Caravan P., Molecular imaging of fibrin in a breast cancer xenograft mouse model. Invest Radiol. 2012; 47 (10): 553-8.
4. Avnet S, Longhi A, Salerno M, et al. Increased osteoclast activity is associated with aggressiveness of osteosarcoma. Int J Oncol. 2008; 33 (6): 1231-8.
5. Yin D, Jia T, Gong W, et al. VEGF blockade decelerates the growth of a murine experimental osteosarcoma. Int J Oncol. 2008; 33 (2): 253-9.
6. Luu HH, Kang Q, Park JK, et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis. 2005; 22 (4): 319-29.
7. Battaglia S, Dumoucel S, Chesneau J, et al. Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient. J Bone Miner Res. 2011; 26 (10): 2439-51.
8. Goldsby RE, Fan TM, Villaluna D, et al. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Eur J Cancer. 2013; 49 (10): 2384-91.
9. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L., An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis. 2000; 18 (3): 261-71.
10. Schmidt J, Strauss GP, Schon A, et al. Establishment and characterization of osteogenic cell lines from a spontaneous murine osteosarcoma. Differentiation. 1988; 39 (3): 151-60.
11. Ichikawa J, Cole HA, Magnussen RA, et al. Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: procoagulant nature of osteosarcoma. Cancer. 2012; 118 (9): 2494-506.
12. Odri GA, Dumoucel S, Picarda G, et al. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res. 2010; 70 (19): 7610-9.
13. Daubine F, Le Gall C, Gasser J, Green J, Clezardin P., Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst. 2007; 99 (4): 322-30.
14. Cole HA, Ichikawa J, Colvin DC, O'Rear L, Schoenecker JG., Quantifying intra-osseous growth of osteosarcoma in a murine model with radiographic analysis. J Orthop Res. 2011; 29 (12): 1957-62.
15. Yarmish G, Klein MJ, Landa J, Lefkowitz RA, Hwang S., Imaging characteristics of primary osteosarcoma: nonconventional subtypes. Radiographics. 2010; 30 (6): 1653-72.
16. Murphey MD, Jelinek JS, Temple HT, Flemming DJ, Gannon FH., Imaging of periosteal osteosarcoma: radiologic-pathologic comparison. Radiology. 2004; 233 (1): 129-38.
17. Weiss KR, Cooper GM, Jadlowiec JA., McGough RL 3rd, Huard J. VEGF and BMP expression in mouse osteosarcoma cells. Clin Orthop Relat Res. 2006; 450: 111-7.
18. Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011; 475 (7355): 222-5.
19. Mizutani K, Sud S, McGregor NA, et al. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia. 2009; 11 (11): 1235-42.
20. Viereck V, Emons G, Lauck V, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun. 2002; 291 (3): 680-6.
21. Tsubaki M, Satou T, Itoh T, et al. Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2. Mol Cell Endocrinol. 2012; 361 (1-2): 219-31.
22. Gallo M, De Luca A, Lamura L, Normanno N., Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol. 2012; 23 (3): 597-604.
23. Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A., Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int. 2006; 17 (5): 693-703.
24. Mercatali L, Ricci M, Scarpi E, et al. RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study. Int J Mol Sci. 2013; 14 (6): 10683-93.
25. Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Vaananen HK., Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab. 2006; 52 (9-10): 499-509.
26. Taylor R, Knowles HJ, Athanasou NA., Ewing sarcoma cells express RANKL and support osteoclastogenesis. J Pathol. 2011; 225 (2): 195-202.
27. Lau YS, Adamopoulos IE, Sabokbar A, Giele H, Gibbons CL, Athanasou NA., Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma. Br J Cancer. 2007; 96 (11): 1716-22.
28. Penno H, Nilsson O, Brandstrom H, Winqvist O, Ljunggren O., Expression of RANK-ligand in prostate cancer cell lines. Scand J Clin Lab Invest. 2009; 69 (1): 151-5.
29. Fujita K, Iwasaki M, Ochi H, et al. Vitamin E decreases bone mass by stimulating osteoclast fusion. Nat Med. 2012; 18 (4): 589-94.
30. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ., Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999; 20 (3): 345-57.
31. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89 (2): 309-19.
32. Danks L, Takayanagi H., Immunology and bone. J Biochem. 2013; 154 (1): 29-39.
33. Lee JA, Jung JS, Kim DH, et al. RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma. Pediatr Blood Cancer. 2011; 56 (5): 738-43.
34. Rousseau J, Escriou V, Lamoureux F, et al. Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models. J Bone Miner Res. 2011; 26 (10): 2452-62.
35. Lynch CC, Hikosaka A, Acuff HB, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell. 2005; 7 (5): 485-96.
36. Mizuno A, Kanno T, Hoshi M, et al. Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J Bone Miner Metab. 2002; 20 (6): 337-44.
37. Boyce BF, Xing L., Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007; 9 (Suppl 1): S1.
38. Brennecke P, Arlt MJ, Muff R, et al. Expression of the chemokine receptor CXCR7 in CXCR4-expressing human 143B osteosarcoma cells enhances lung metastasis of intratibial xenografts in SCID mice. PLoS One. 2013; 8 (9): e74045.
39. Wang SW, Wu HH, Liu SC, et al. CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma. PLoS One. 2012; 7 (4): e35101.
40. Endo-Munoz L, Cumming A, Rickwood D, et al. Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases. Cancer Res. 2010; 70 (18): 7063-2.
41. Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer. 2009; 115 (22): 5339-48.
42. New DC, Wong YH., CC chemokine receptor-coupled signalling pathways. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2003; 35 (9): 779-88.
43. Solinas G, Germano G, Mantovani A, Allavena P., Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009; 86 (5): 1065-73.
44. Endo-Munoz L, Evdokiou A, Saunders NA., The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis. Biochim Biophys Acta. 2012; 1826 (2): 434-42.
45. Kim MS, Day CJ, Morrison NA., MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J Biol Chem. 2005; 280 (16): 16163-9.
46. Bussard KM, Venzon DJ, Mastro AM., Osteoblasts are a major source of inflammatory cytokines in the tumor microenvironment of bone metastatic breast cancer. J Cell Biochem. 2010; 111 (5): 1138-48.
47. Buddingh EP, Kuijjer ML, Duim RA, et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res. 2011; 17 (8): 2110-9.
48. Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011; 29 (9): 1221-7.
49. Kim JY, Lee EY, Lee EB, et al. Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis. Arthritis Res Ther. 2012; 14 (4): R187.
50. Romano M, Diomede L, Sironi M, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest. 2000; 80 (7): 1095-100.